GlassScriptPhysician profile
Said I Jacob
NPI 1528128949
$939,592.12
in general payments reported to CMS, 2019-2025
38 companies · $198K in 2025
The $198K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104K · 2020: $45K · 2021: $67K · 2022: $129K · 2023: $206K · 2024: $191K · 2025: $198K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $495K · Consulting Fee: $38K · Food and Beverage: $31K · Travel and Lodging: $28K · Honoraria: $2,550 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $495,124.40 |
| Consulting Fee | $37,895.04 |
| Food and Beverage | $31,131.02 |
| Travel and Lodging | $28,092.10 |
| Honoraria | $2,550.00 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $330,226.27 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $191,143.26 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $158,539.42 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $127,594.68 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Abbvie INC. | $54,094.45 | 2021-2025 | |
| Allergan, INC. | $23,753.13 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $17,257.87 | 2022-2024 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14,714.50 | 2020-2025 | Caplyta |
| Lundbeck LLC | $5,069.73 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $4,112.92 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $2,511.66 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $2,330.34 | 2019-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $2,185.15 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $1,319.76 | 2023-2025 | Auvelity, Sunosi |
| Janssen Pharmaceuticals, INC | $1,245.88 | 2019-2025 | Invega Sustenna, Invega Trinza |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Said Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.